828 related articles for article (PubMed ID: 16503501)
1. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
4. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
5. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
6. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
8. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
9. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G
Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484
[TBL] [Abstract][Full Text] [Related]
10. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
11. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma.
Goldschmidt H; Hegenbart U; Haas R; Hunstein W
Bone Marrow Transplant; 1996 May; 17(5):691-7. PubMed ID: 8733683
[TBL] [Abstract][Full Text] [Related]
12. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Reiser M; Josting A; Draube A; Mapara MY; Scheid C; Chemnitz J; Tesch H; Wolf J; Diehl V; Söhngen D; Engert A
Bone Marrow Transplant; 1999 Jun; 23(12):1223-8. PubMed ID: 10414907
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
14. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
17. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
19. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
